228 results
8-K
VBIVQ
VBI Vaccines Inc
29 May 24
VBI Vaccines Announces New Tumor Response Data from Ongoing Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma Patients
8:00am
cancer vaccine candidate, in recurrent glioblastoma (rGBM) patients. The Company undertakes no obligation to update, supplement or amend the materials
8-K
EX-1.1
VBIVQ
VBI Vaccines Inc
15 May 24
VBI Vaccines Reports First Quarter 2024 Financial Results
4:18pm
such material) (the foregoing materials, including the exhibits thereto and documents incorporated by reference therein, together with the Prospectus … or wastes (collectively, “Hazardous Materials”) into the environment, or otherwise relating to the manufacture, processing, distribution, use, treatment
424B5
VBIVQ
VBI Vaccines Inc
15 May 24
Prospectus supplement for primary offering
4:16pm
term extensions or expansions of leased space;
the ability of our vendors and suppliers to manufacture and deliver materials in a timely manner … and suppliers to manufacture and deliver materials in a timely manner that meet regulatory agency and our standards and requirements to meet planned timelines
DEFA14A
ht8e6
29 Apr 24
Additional proxy soliciting materials
4:10pm
8-K
dmb0hls7
11 Apr 24
VBI Vaccines Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
4:07pm
8-K
EX-10.1
1ncnit lmz
11 Apr 24
VBI Vaccines Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
4:07pm
424B5
rlxgrei31
11 Apr 24
Prospectus supplement for primary offering
9:06am
8-K
3r0wd6rzhgr
3 Apr 24
VBI Vaccines Presents Encouraging Early Tumor Response Data From Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma
8:00am
8-K
v9n0jr6x46etltzxxn
2 Apr 24
VBI Vaccines Announces Expanded Strategic Partnership with Canadian Government to Advance mRNA-Launched eVLP (MLE) Vaccine Platform
8:00am
8-K
eybvyvxa
20 Nov 23
Regulation FD Disclosure
8:00am